Biogen Inc BIIB:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 01/27/23 EST
290.08UNCH (UNCH)
Volume
27,183
Close
290.08quote price arrow down-1.84 (-0.63%)
Volume
866,699
52 week range
187.16 - 311.88
Loading...
  • Open292.36
  • Day High295.90
  • Day Low289.94
  • Prev Close291.92
  • 52 Week High311.88
  • 52 Week High Date11/30/22
  • 52 Week Low187.16
  • 52 Week Low Date05/09/22

Key Stats

  • Market Cap41.772B
  • Shares Out144.00M
  • 10 Day Average Volume1.02M
  • Dividend-
  • Dividend Yield-
  • Beta0.22
  • YTD % Change4.75

KEY STATS

  • Open292.36
  • Day High295.90
  • Day Low289.94
  • Prev Close291.92
  • 52 Week High311.88
  • 52 Week High Date11/30/22
  • 52 Week Low187.16
  • 52 Week Low Date05/09/22
  • Market Cap41.772B
  • Shares Out144.00M
  • 10 Day Average Volume1.02M
  • Dividend-
  • Dividend Yield-
  • Beta0.22
  • YTD % Change4.75

RATIOS/PROFITABILITY

  • EPS (TTM)19.63
  • P/E (TTM)14.78
  • Fwd P/E (NTM)18.33
  • EBITDA (TTM)3.398B
  • ROE (TTM)24.69%
  • Revenue (TTM)10.363B
  • Gross Margin (TTM)77.15%
  • Net Margin (TTM)22.88%
  • Debt To Equity (MRQ)49.15%

EVENTS

  • Earnings Date02/15/2023
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Related Video

Friday, Jan. 20, 2023: Cramer wants to load up on this stock
VIDEO10:1510:15
CNBC Investing ClubFriday, Jan. 20, 2023: Cramer wants to load up on this stock

Profile

MORE
Biogen Inc. is a global biopharmaceutical company. It is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA...
Stelios Papadopoulos Ph.D.
Independent Chairman of the Board
Christopher Viehbacher
President, Chief Executive Officer, Director